TKPHF News and Press, Takeda Pharmaceutical Co Ltd From 03/07/24

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

2024-03-05 09:54:23 ET Summary Takeda wins FDA approval for the first oral treatment for Eosinophilic esophagitis (EoE) in the US. The market size for EoE is expected to reach $941.8 million by 2031. Takeda's new CFO, Milano Furuta, will focus on growth and increasing sharehol...

Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...

Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...

IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...

Takeda Pharmaceutical Co (TKPHF) is expected to report for Q3 2024

2024-02-01 01:21:16 ET More on Takeda Pharmaceutical EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze Takeda wins EU approval for Hyqvia CIDP indication Seeking Alpha’s Quant Rating on Takeda Pharmaceutical Historical earnings data for Ta...

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

2024-01-03 03:21:42 ET Summary Results from phase 3 KONFIDENT trial, using sebetralstat for on-demand treatment of patients with HAE, expected early 2024. Upon primary endpoint of PGI-C score being met, NDA filing of sebetralstat for HAE expected 1st half of 2024; European and Jap...

2023-12-18 11:24:00 ET Summary Wave Life Sciences Ltd. raised $100 million in a discounted public offering, causing a decline in their stock price. The market reaction may have been incorrect, as the company has positive proof of concept data and major partnerships with Takeda and...